Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Puttemans, Janik, Dekempeneer, Yana, Eersels, Jos L., Hanssens, Heleen, Debie, Pieterjan, Keyaerts, Marleen, Windhorst, Albert D., van der Aa, Frank, Lecocq, Quentin, Breckpot, Karine, Morgenstern, Alfred, Bruchertseifer, Frank, Lahoutte, Tony, Devoogdt, Nick, D’Huyvetter, Matthias
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226418/
https://ncbi.nlm.nih.gov/pubmed/32326199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041017
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller